Skip to main content

Table 2 Associations between genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 and breast cancer and prostate cancer

From: Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer

Outcome

Case, No

OR (95% CI)

P valuea

HMG-CoA reductase

Breast cancer

122,977

0.84 (0.74–0.95)

0.005

Prostate cancer

79,148

0.85 (0.73–1.00)

0.05

NPC1L1

Breast cancer

122,977

0.72 (0.58–0.90)

0.005

Prostate cancer

79,148

1.23 (0.92–1.63)

0.16

PCSK9

Breast cancer

122,977

0.92 (0.86–0.98)

0.01

Prostate cancer

79,148

0.81 (0.73–0.90)

4.52e−05

  1. HMG-CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A; NPC1L1, Niemann-Pick C1-Like 1; PCSK9, proprotein convertase subtilisin/kexin type 9; OR, Odds Ratio; CI, confidence interval
  2. aSignificance threshold was set at P < 0.008 (Bonferroni-correction significance threshold calculated as 0.05 divided by 6 [3 drug targets against 2 outcomes])